MX2019007801A - Tratamiento de cáncer avanzado con expresión de her2. - Google Patents

Tratamiento de cáncer avanzado con expresión de her2.

Info

Publication number
MX2019007801A
MX2019007801A MX2019007801A MX2019007801A MX2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A
Authority
MX
Mexico
Prior art keywords
her2
treatment
cancer
advanced
amplified
Prior art date
Application number
MX2019007801A
Other languages
English (en)
Spanish (es)
Inventor
Beattie Mary
Brammer Melissa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60957441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019007801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019007801A publication Critical patent/MX2019007801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019007801A 2016-12-28 2017-12-14 Tratamiento de cáncer avanzado con expresión de her2. MX2019007801A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662439815P 2016-12-28 2016-12-28
US201762457672P 2017-02-10 2017-02-10
US201762519599P 2017-06-14 2017-06-14
PCT/US2017/066286 WO2018125589A1 (en) 2016-12-28 2017-12-14 Treatment of advanced her2 expressing cancer

Publications (1)

Publication Number Publication Date
MX2019007801A true MX2019007801A (es) 2019-10-30

Family

ID=60957441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007801A MX2019007801A (es) 2016-12-28 2017-12-14 Tratamiento de cáncer avanzado con expresión de her2.

Country Status (11)

Country Link
US (2) US20180221481A1 (enExample)
EP (1) EP3562844A1 (enExample)
JP (2) JP6914336B2 (enExample)
KR (1) KR102313262B1 (enExample)
CN (1) CN110099926A (enExample)
AU (2) AU2017387909A1 (enExample)
CA (1) CA3046092A1 (enExample)
IL (1) IL267675A (enExample)
MX (1) MX2019007801A (enExample)
TW (1) TW201827077A (enExample)
WO (1) WO2018125589A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9815904B2 (en) 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
EP3807640A4 (en) * 2018-06-14 2022-04-13 Memorial Sloan Kettering Cancer Center METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES
CN114025795B (zh) * 2019-05-31 2025-04-29 酵活英属哥伦比亚有限公司 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.
WO2022022526A1 (zh) * 2020-07-28 2022-02-03 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN115957321A (zh) * 2023-03-03 2023-04-14 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
SI0950067T1 (sl) 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
DE69907439T3 (de) 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU782325B2 (en) 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
MXPA01013395A (es) 1999-06-25 2003-09-04 Genentech Inc Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6754305B1 (en) 1999-08-02 2004-06-22 Therma-Wave, Inc. Measurement of thin films and barrier layers on patterned wafers with X-ray reflectometry
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US6695940B2 (en) 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
US6982719B2 (en) 2002-07-15 2006-01-03 Sun Microsystems, Inc. Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
AU2003273218C1 (en) 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
US7129840B2 (en) 2002-09-03 2006-10-31 Ricoh Company, Ltd. Document security system
US20040258685A1 (en) 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
US7195440B2 (en) 2004-05-27 2007-03-27 Lambert Charles F Agricultural silo auger system apparatus and method
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20070148131A1 (en) 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2636074A1 (en) * 2006-01-04 2007-07-12 University Of Montpellier 1 Combination therapy using anti-egfr and anti-her2 antibodies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20080038271A1 (en) 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
BRPI0812777A2 (pt) 2007-06-06 2014-12-02 Hoffmann La Roche Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AU2009221729A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and HER antagonists
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2832174C (en) * 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
PT4403228T (pt) * 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
US9815904B2 (en) * 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
KR20160141857A (ko) * 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016201454A1 (en) * 2015-06-12 2016-12-15 The Translational Genomics Research Institute Targeted therapies for cancer

Also Published As

Publication number Publication date
US20180221481A1 (en) 2018-08-09
KR20190094228A (ko) 2019-08-12
JP6914336B2 (ja) 2021-08-04
AU2017387909A1 (en) 2019-06-27
CN110099926A (zh) 2019-08-06
US20200237910A1 (en) 2020-07-30
JP2021178832A (ja) 2021-11-18
TW201827077A (zh) 2018-08-01
CA3046092A1 (en) 2018-07-05
EP3562844A1 (en) 2019-11-06
JP7234303B2 (ja) 2023-03-07
KR102313262B1 (ko) 2021-10-14
AU2021201516A1 (en) 2021-04-01
JP2020514281A (ja) 2020-05-21
WO2018125589A1 (en) 2018-07-05
IL267675A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019007801A (es) Tratamiento de cáncer avanzado con expresión de her2.
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MY189536A (en) Subcutaneous her2 antibody formulations
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2017011374A (es) Método de tratamiento de cáncer asociado con una mutación de ras.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
PL3565844T3 (pl) Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
DK2766040T3 (da) Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PL3581182T3 (pl) Kombinacja lecząca nowotwór złośliwy gruczołu krokowego, kompozycja farmaceutyczna i sposób leczenia
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
HK1258319A1 (zh) 癌症疗法
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.